Merck

The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Sun, 06/16/19 - 05:41 pm
FDA
Merck
Arqule
Affimed
BeiGene
Epizyme
MorphoSys
Theravance
Allena Pharma
Akero Therapeutics
Atreca
Dermavant Sciences
Personalis
Prevail Therapeutics
Stoke Therapeutics
IPOs
Amgen, Lilly, Merck sue HHS to block price disclosures in DTC ads
BioCentury
Fri, 06/14/19 - 06:26 pm
HHS
DTC ads
television ads
Merck
Eli Lilly
Amgen
Merck's Full Court Press On Oncology
Forbes
Fri, 06/14/19 - 06:22 pm
Merck
oncology
R&D
M&A
Tilos Therapeutics
Merck helps FDA test blockchain for track and trace
Fierce Pharma
Thu, 06/13/19 - 10:10 am
Merck
FDA
blockchain
track and trace
supply chain
House progressives challenge drugmakers to come back to Capitol Hill
Stat
Wed, 06/12/19 - 06:52 pm
Democrats
drug pricing
Pfizer
Merck
Eli Lilly
Gilead Sciences
Mylan
Mallinckrodt
Merck's Keytruda wins FDA approval to treat head and neck cancer
Yahoo/Reuters
Tue, 06/11/19 - 09:31 am
Merck
FDA
head and neck cancer
Merck Bags Tilos, Adding an Immunotherapy Booster to Its Arsenal
Xconomy
Mon, 06/10/19 - 09:41 am
Merck
M&A
Tilos Therapeutics
cancer immunotherapy
oncology
BIO Roundup: Agenus, FDA, Merck’s Frazier and Much More
BioSpace
Sun, 06/9/19 - 01:49 pm
Agenus
Jamie Dimon
BIO 2019
RWE
FDA
immuno-oncology
Merck
Ken Frazier
UK
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
Sun, 06/9/19 - 01:36 pm
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
From BIO meeting, Merck CEO Ken Frazier defends capitalism, drug industry
Biopharma Dive
Wed, 06/5/19 - 07:29 pm
Merck
Pharma CEOs
Ken Frazier
BIO 2019
capitalism
drug pricing
After three-decade Merck career, Adam Schechter jumps for LabCorp CEO job
Fierce Pharma
Wed, 06/5/19 - 07:25 pm
Merck
LapCorp
Adam Schechter
diagnostics
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
Xconomy
Wed, 06/5/19 - 10:43 am
ASCO 2019
cancer
immunotherapy
diagnostics
Veracyte
Grail
Moderna Therapeutics
Amgen
Nektar Therapeutics
Blueprint Medicines
Merck
AstraZeneca
Roche
breast cancer
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
Fierce Pharma
Tue, 06/4/19 - 12:18 pm
ASCO 2019
Merck
Keytruda
FDA
Pfizer
AstraZeneca
Regeneron
Libtayo
Venclexta
Gazyva
3 Drug Stocks That Could Win From Key FDA Approvals in June
Motley Fool
Tue, 06/4/19 - 10:59 am
Merck
Amag Pharmaceuticals
Alexion Pharma
FDA
Keytruda
Vyleesi
Soliris
ASCO 2019 – The results of clinical practices changing phase III studies
Pharmaforum
Mon, 06/3/19 - 11:32 pm
clinical trials
ASCO 2019
Merck
AstraZeneca
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
BioCentury
Mon, 06/3/19 - 08:17 pm
ASCO 2019
Celgene
Multiple Myeloma
Five Prime Therapeutics
Iovance
Merck
Moderna Therapeutics
Eli Lilly
ICR
Years after Cubist buyout, Merck scores a new Zerbaxa indication. Can it jump-start sales?
Fierce Pharma
Mon, 06/3/19 - 07:45 pm
Merck
Cubist Pharma
Zerbaxa
FDA
hospital-acquired infections
ASCO 2019 day three
Pharmaforum
Sun, 06/2/19 - 01:09 pm
ASCO 2019
Merck
AstraZeneca
pancreatic cancer
Novartis
alpelisib
Roche
entrectinib
ASCO 2019 day two
Pharmaforum
Sun, 06/2/19 - 01:01 pm
Gilead Sciences
Kite Pharma
KTE-X19
CAR-T
ASCO 2019
Novartis
Merck
Keytruda
spartalizumab
Mark Your Calendar For These June PDUFA Dates
Yahoo/Benzinga
Sat, 06/1/19 - 12:52 pm
FDA
Merck
Zerbaxa
XERIS
Gvoke HypoPen
Keytruda
Amag Pharmaceuticals
Palatin
Vyleesi
Acer Therapeutics
Edsivo
Sanofi
Regeneron
Dupixent
Alexion
Soliris
Retrophin
Thiola
Allergan
Botox

Pages